Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) independent director
Independent opinions on the relevant proposals of the 10th meeting (interim meeting) of the ninth board of directors. As an independent director of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) (hereinafter referred to as the "company"), in accordance with the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 1 - standardized operation of listed companies on the main board, the stock listing rules of Shenzhen Stock Exchange and the articles of association of the company, Independent opinions on the relevant proposals considered at the 10th meeting (interim meeting) of the ninth board of directors held on March 3, 2022 are as follows:
1、 Independent opinions of independent directors on matters related to the company's use of temporarily idle raised funds for cash management
At present, the company's operation is in good condition, and the construction of raised investment projects is steadily advancing. On the premise of ensuring the normal use plan of the company's raised funds and ensuring the safety of the raised funds, it is agreed to use the temporarily idle raised funds with an amount of no more than 600 million yuan for cash management. The company's cash management of temporarily idle raised funds is conducive to improving the use efficiency of idle raised funds and increasing the company's investment income, which is in line with the interests of the company and all shareholders. The company uses the temporarily idle raised funds for cash management, and there is no situation that affects the normal progress of the investment projects of the raised funds or changes the investment purpose of the raised funds in a disguised form, and there is no situation that damages the interests of the company and all shareholders, especially the minority shareholders. The company has performed the necessary decision-making procedures for the cash management of the temporarily idle raised funds, which is in line with the provisions of relevant laws, regulations and normative documents.
Based on independent judgment, the independent directors of the company unanimously agreed that the company would continue to use the temporarily idle raised funds of no more than 600 million yuan for cash management.
2、 Independent opinions of independent directors on matters related to the company's use of idle raised funds to temporarily supplement working capital
Part of the idle raised funds used by the company this time shall not exceed 250 million yuan to temporarily supplement the working capital, which will not affect the normal progress of the raised investment project, and there is no situation of changing the investment direction of the raised funds in a disguised manner and damaging the interests of the company and all shareholders, especially the minority shareholders. The use period of the raised funds shall not exceed 12 months from the expiration date of the authorization at the fourth meeting of the ninth board of directors (April 19, 2022), and the corresponding approval procedures have been performed, Comply with the relevant provisions of the guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 - standardized operation of listed companies on the main board.
Based on independent judgment, the independent directors of the company unanimously agreed that the company would continue to use some idle raised funds of no more than 250 million yuan to temporarily supplement working capital.
3、 Independent opinions of independent directors on the subsidiary's application for bank credit and guarantee for the subsidiary in 2022
Guangdong Shuanglin biopharmaceutical Co., Ltd. and Harbin paisficho biopharmaceutical Co., Ltd. are wholly-owned subsidiaries of the company, with good operation and normal and stable cash flow. The guarantee matters have required the guaranteed unit to provide counter guarantee with all assets, which can effectively control the guarantee risk. The company's guarantee for wholly-owned subsidiaries has fulfilled the corresponding decision-making and approval procedures, and there is no behavior damaging the interests of the company and minority shareholders. We unanimously agreed to submit the proposal to the general meeting of shareholders for deliberation.
(there is no text on this page, which is the signature page of Pacific Shuanglin Bio-Pharmacy Co.Ltd(000403) independent directors' independent opinions on relevant proposals of the 10th meeting of the ninth board of directors): Independent Directors:
Zhang Shengjie, Yu Junxian, he Qing
Wang Xian'an, Dong Zuojun
March 3, 2002
